Matching articles for "Mifeprex"

In Brief: Alternatives to Mifepristone for Medication Abortion

   
The Medical Letter on Drugs and Therapeutics • June 26, 2023;  (Issue 1679)
The possibility that use of mifepristone (Mifeprex, and generics) may be restricted has led to questions about alternatives for medication...
The possibility that use of mifepristone (Mifeprex, and generics) may be restricted has led to questions about alternatives for medication abortion.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):102-3 | Show Full IntroductionHide Full Introduction

In Brief: Expanded Access to Mifepristone

   
The Medical Letter on Drugs and Therapeutics • February 20, 2023;  (Issue 1670)
First approved in 2000 for termination of pregnancies of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone (Mifeprex, and generics) was expanded in 2016 to include pregnancies...
First approved in 2000 for termination of pregnancies of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone (Mifeprex, and generics) was expanded in 2016 to include pregnancies of up to 10 weeks' gestation. A single 200-mg oral dose of mifepristone followed 24-48 hours later by a single 800-mcg buccal dose of the prostaglandin analog misoprostol terminates early intrauterine pregnancies in about 95% of women.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):31 | Show Full IntroductionHide Full Introduction

In Brief: Mifepristone by Mail for Pregnancy Termination

   
The Medical Letter on Drugs and Therapeutics • January 24, 2022;  (Issue 1642)
The FDA has removed the requirement that mifepristone (Mifeprex, and generics), a progestin receptor antagonist approved for use in a regimen with the prostaglandin E1 analog misoprostol (Cytotec, and...
The FDA has removed the requirement that mifepristone (Mifeprex, and generics), a progestin receptor antagonist approved for use in a regimen with the prostaglandin E1 analog misoprostol (Cytotec, and generics) for medical termination of pregnancy, must be dispensed in person to the patient.
Med Lett Drugs Ther. 2022 Jan 24;64(1642):11 | Show Full IntroductionHide Full Introduction

Mifepristone (Mifeprex) Label Changes

   
The Medical Letter on Drugs and Therapeutics • April 25, 2016;  (Issue 1493)
The FDA has approved several significant changes in the labeling of mifepristone (Mifeprex – Danco), an oral antiprogestin that has been used in the US for more than 15 years for termination of...
The FDA has approved several significant changes in the labeling of mifepristone (Mifeprex – Danco), an oral antiprogestin that has been used in the US for more than 15 years for termination of intrauterine pregnancy. It has generally been used with the prostaglandin analog misoprostol (Cytotec, and generics).
Med Lett Drugs Ther. 2016 Apr 25;58(1493):55-6 | Show Full IntroductionHide Full Introduction

Misoprostol for Miscarriage

   
The Medical Letter on Drugs and Therapeutics • March 4, 2013;  (Issue 1411)
Misoprostol (Cytotec, and generics), a prostaglandin E1 analog FDA-approved for prevention of NSAID-induced gastric ulcers and, when taken with mifepristone (Mifeprex), for termination of early intrauterine...
Misoprostol (Cytotec, and generics), a prostaglandin E1 analog FDA-approved for prevention of NSAID-induced gastric ulcers and, when taken with mifepristone (Mifeprex), for termination of early intrauterine pregnancy, has also been used off-label for years for medical management of first-trimester spontaneous abortion (miscarriage).
Med Lett Drugs Ther. 2013 Mar 4;55(1411):19-20 | Show Full IntroductionHide Full Introduction

Mifepristone (RU 486)

   
The Medical Letter on Drugs and Therapeutics • October 30, 2000;  (Issue 1091)
Mifepristone (RU 486; Mifeprex - Danco), an antiprogestin, has been approved by the FDA for termination of intrauterine pregnancies of 49 days or less. It is generally used with misoprostol (Cytotec - Searle),...
Mifepristone (RU 486; Mifeprex - Danco), an antiprogestin, has been approved by the FDA for termination of intrauterine pregnancies of 49 days or less. It is generally used with misoprostol (Cytotec - Searle), an E1 prostaglandin analog marketed in the USA only for prevention of gastric ulcers.
Med Lett Drugs Ther. 2000 Oct 30;42(1091):101-2 | Show Full IntroductionHide Full Introduction